Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Horizon Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Rule 17(e) Announcement - Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 17(d) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.